311 related articles for article (PubMed ID: 22145272)
1. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
2. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Richardson PG; Weller E; Jagannath S; Avigan DE; Alsina M; Schlossman RL; Mazumder A; Munshi NC; Ghobrial IM; Doss D; Warren DL; Lunde LE; McKenney M; Delaney C; Mitsiades CS; Hideshima T; Dalton W; Knight R; Esseltine DL; Anderson KC
J Clin Oncol; 2009 Dec; 27(34):5713-9. PubMed ID: 19786667
[TBL] [Abstract][Full Text] [Related]
3. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Richardson PG; Siegel DS; Vij R; Hofmeister CC; Baz R; Jagannath S; Chen C; Lonial S; Jakubowiak A; Bahlis N; Song K; Belch A; Raje N; Shustik C; Lentzsch S; Lacy M; Mikhael J; Matous J; Vesole D; Chen M; Zaki MH; Jacques C; Yu Z; Anderson KC
Blood; 2014 Mar; 123(12):1826-32. PubMed ID: 24421329
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Jakubowiak AJ; Griffith KA; Reece DE; Hofmeister CC; Lonial S; Zimmerman TM; Campagnaro EL; Schlossman RL; Laubach JP; Raje NS; Anderson T; Mietzel MA; Harvey CK; Wear SM; Barrickman JC; Tendler CL; Esseltine DL; Kelley SL; Kaminski MS; Anderson KC; Richardson PG
Blood; 2011 Jul; 118(3):535-43. PubMed ID: 21596852
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Richardson PG; Weller E; Lonial S; Jakubowiak AJ; Jagannath S; Raje NS; Avigan DE; Xie W; Ghobrial IM; Schlossman RL; Mazumder A; Munshi NC; Vesole DH; Joyce R; Kaufman JL; Doss D; Warren DL; Lunde LE; Kaster S; Delaney C; Hideshima T; Mitsiades CS; Knight R; Esseltine DL; Anderson KC
Blood; 2010 Aug; 116(5):679-86. PubMed ID: 20385792
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Ocio EM; Vilanova D; Atadja P; Maiso P; Crusoe E; Fernández-Lázaro D; Garayoa M; San-Segundo L; Hernández-Iglesias T; de Alava E; Shao W; Yao YM; Pandiella A; San-Miguel JF
Haematologica; 2010 May; 95(5):794-803. PubMed ID: 19951978
[TBL] [Abstract][Full Text] [Related]
7. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J; Doss D; Zaki MH; Bensmaine A; Herring J; Li Y; Watkins L; Chen MS; Anderson KC
Leukemia; 2017 Dec; 31(12):2695-2701. PubMed ID: 28642620
[TBL] [Abstract][Full Text] [Related]
8. Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.
Kristinsson SY; Landgren O; Rajkumar VS
Cancer J; 2009; 15(6):473-8. PubMed ID: 20010166
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.
Jacobus SJ; Rajkumar SV; Weiss M; Stewart AK; Stadtmauer EA; Callander NS; Dreosti LM; Lacy MQ; Fonseca R
Blood Cancer J; 2016 Jul; 6(7):e448. PubMed ID: 27471864
[No Abstract] [Full Text] [Related]
10. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.
Paludo J; Mikhael JR; LaPlant BR; Halvorson AE; Kumar S; Gertz MA; Hayman SR; Buadi FK; Dispenzieri A; Lust JA; Kapoor P; Leung N; Russell SJ; Dingli D; Go RS; Lin Y; Gonsalves WI; Fonseca R; Bergsagel PL; Roy V; Sher T; Chanan-Khan AA; Ailawadhi S; Stewart AK; Reeder CB; Richardson PG; Rajkumar SV; Lacy MQ
Blood; 2017 Sep; 130(10):1198-1204. PubMed ID: 28684537
[TBL] [Abstract][Full Text] [Related]
11. Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.
Leleu X; Kyriakou C; Vande Broek I; Murphy P; Bacon P; Lewis P; Gilet H; Arnould B; Petrucci MT
Blood Cancer J; 2017 Mar; 7(3):e543. PubMed ID: 28304402
[TBL] [Abstract][Full Text] [Related]
12. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Dunavin NC; Wei L; Elder P; Phillips GS; Benson DM; Hofmeister CC; Penza S; Greenfield C; Rose KS; Rieser G; Merritt L; Ketcham J; Heerema N; Byrd JC; Devine SM; Efebera YA
Leuk Lymphoma; 2013 Aug; 54(8):1658-64. PubMed ID: 23194056
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison.
Weisel K; Dimopoulos MA; Beksac M; Leleu X; Richter J; Heeg B; Patel S; Majer I; McFadden I; Mikhael J
Leuk Lymphoma; 2024 Apr; 65(4):481-492. PubMed ID: 38345269
[TBL] [Abstract][Full Text] [Related]
14. Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
Mori S; Crawford BS; Roddy JV; Phillips G; Elder P; Hofmeister CC; Efebera Y; Benson DM
Hematol Oncol; 2012 Sep; 30(3):156-62. PubMed ID: 22028144
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
Voorhees PM; Manges RF; Sonneveld P; Jagannath S; Somlo G; Krishnan A; Lentzsch S; Frank RC; Zweegman S; Wijermans PW; Orlowski RZ; Kranenburg B; Hall B; Casneuf T; Qin X; van de Velde H; Xie H; Thomas SK
Br J Haematol; 2013 May; 161(3):357-66. PubMed ID: 23432640
[TBL] [Abstract][Full Text] [Related]
16. New therapies in multiple myeloma.
Merchionne F; Perosa F; Dammacco F
Clin Exp Med; 2007 Sep; 7(3):83-97. PubMed ID: 17972050
[TBL] [Abstract][Full Text] [Related]
17. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.
Shah JJ; Feng L; Thomas SK; Berkova Z; Weber DM; Wang M; Qazilbash MH; Champlin RE; Mendoza TR; Cleeland C; Orlowski RZ
Blood Cancer J; 2016 Feb; 6(2):e396. PubMed ID: 26871714
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Mushtaq A; Kapoor V; Latif A; Iftikhar A; Zahid U; McBride A; Abraham I; Riaz IB; Anwer F
Crit Rev Oncol Hematol; 2018 May; 125():1-11. PubMed ID: 29650268
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.
Ghosh N; Ye X; Ferguson A; Huff CA; Borrello I
Br J Haematol; 2011 Mar; 152(5):593-9. PubMed ID: 21241279
[TBL] [Abstract][Full Text] [Related]
20. Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.
Giles SL; Messiou C; Collins DJ; Morgan VA; Simpkin CJ; West S; Davies FE; Morgan GJ; deSouza NM
Radiology; 2014 Jun; 271(3):785-94. PubMed ID: 24475858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
